Ovarian Cancer Clinical Trial

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Summary

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

View Full Description

Full Description

The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5 mm.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

candidate for primary CRS
histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer

Exclusion Criteria:

history of previous malignancies within 5 years prior to inclusion
FIGO stage IV disease
complete primary cytoreduction is impossible
prior treatment for the current malignancy

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

538

Study ID:

NCT03772028

Recruitment Status:

Recruiting

Sponsor:

The Netherlands Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

MSKCC New York
New York New York, 10065, United States More Info
Bhavani Ramesh
Contact
[email protected]
Oliver Zivanovic
Principal Investigator
Rigshospitalet Copenhagen
Copenhagen , , Denmark More Info
Alice Bjoernlund-Larsen
Contact
[email protected]
Berit Jul Mosgaard
Principal Investigator
o Institut Bergonié, Bordeaux
Bordeaux , , France More Info
Nabila Bouazza
Contact
[email protected]
Frederic Guyon, Dr
Principal Investigator
Centre Leon Berard, Lyon
Lyon , , France More Info
Nabila B Bouazza
Contact
[email protected]
Pierre Meeus, Dr
Principal Investigator
CHU Lyon
Lyon , , France More Info
Nabila B Bouazza
Contact
[email protected]
Naoual Bakrin
Principal Investigator
Institut du Cancer Montpellier
Montpellier , , France More Info
Nabila Bouazza
Contact
[email protected]
Pierre-Emmanuel Colombo, MD
Principal Investigator
Institut de Cancerologie de l'Ouest, ICO Nantes)
Nantes , , France More Info
Nabila Bouazza
Contact
[email protected]
Charlotte Bourgin
Principal Investigator
Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse)
Toulouse , , France More Info
Nabila Bouazza
Contact
[email protected]
Ferron Gwenael
Principal Investigator
Mater Misericordiae University Hospital, Dublin
Dublin , , Ireland More Info
Terri Martin
Contact
[email protected]
Donal Brennan
Principal Investigator
Policlinico Sant'Orsola, Bologna
Bologna , , Italy More Info
Pierandrea De Iaco
Principal Investigator
Fondazione Policlinico A Gemelli IRCCS
Roma , , Italy More Info
Andrea Deamicis
Contact
[email protected]
Anna Fagotti
Principal Investigator
Antoni van leeuwenhoek
Amsterdam Noord-Holland, 1066C, Netherlands More Info
Lot Aronson, PhD student
Contact
[email protected]
Ruby van Stein, PhD student
Contact
[email protected]
Willemien van Driel, dr
Principal Investigator
Amsterdam UMC
Amsterdam , , Netherlands
Catharina Hospital
Eindhoven , , Netherlands
Medisch Spectrum Twente
Enschede , , Netherlands
UMCG
Groningen , , Netherlands
Leiden University Medical Center (LUMC)
Leiden , , Netherlands
Maastricht UMC+
Maastricht , , Netherlands
Radboud MC
Nijmegen , , Netherlands
Erasmus MC
Rotterdam , , Netherlands
Alice Bjoernlund-Larsen
Uppsala , , Sweden More Info
Alice Bjoernlund-Larsen
Contact
[email protected]
Marta Lomnytska
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

538

Study ID:

NCT03772028

Recruitment Status:

Recruiting

Sponsor:


The Netherlands Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.